Aclaris Therapeutics Sees 62% Q4 Gain, Still Down 83% Over Three Years

Aclaris Therapeutics' (ACRS) stock has risen 62% in the last quarter, but its market cap has only increased by $40m in the past 7 days. Despite this, the company's three-year returns have been poor, with investors down 83%. The company's revenue has dropped 0.8% per year over the last three years, and its share price has fallen 22% annually. Insiders have been buying shares, but future earnings will be crucial to determining whether shareholders will make money.